Session Information
Date: Wednesday, September 25, 2019
Session Title: Neuroimaging
Session Time: 1:15pm-2:45pm
Location: Les Muses Terrace, Level 3
Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease.
Background: Recent work has shown loss of PDE10A expression in middle-stage and advanced treated patients with Parkinson’s disease, which was associated with motor symptom severity.
Method: Fifty-four subjects were included in this study (17 early de novo, 15 early levodopa-treated patients with Parkinson’s disease, and 22 controls). All participants underwent [11C]IMA107 PET, [11C]PE2I PET and 3-Tesla MRI scan. We also compared [11C]IMA107 binding in our early population with data from 24 moderate-advanced patients with Parkinson’s disease.
Results: Early de novo Parkinson’s disease patients showed loss of [11C]IMA107 and of [11C]PE2I binding in caudate (P<0.001) and putamen (P<0.001). Compared with de novo, early levodopa-treated Parkinson’s disease patients showed additional [11C]IMA107 binding loss of 10.7% in the caudate (P<0.001; annual decline=3.6%) and 8.4% in the putamen (P<0.001; annual decline=2.8%); whereas [11C]PE2I binding loss of 20.3% in the putamen (P<0.001; annual decline=6.8%). Moderate-advanced patients showed further loss of [11C]IMA107 binding in the pallidum compared to early de novo patients (P<0.001). Lower [11C]IMA107 binding correlated with lower [11C]PE2I binding in the caudate (rho=0.51;P<0.01) and putamen (rho=0.53;P<0.01). Longer disease duration correlated with lower [11C]IMA107 binding in the caudate (rho=-0.72; P<0.001) and putamen (rho=-0.48; P<0.01), and with lower [11C]PE2I binding only in the putamen (rho=-0.65;P<0.001). Higher burden of motor symptoms correlated with lower [11C]IMA107 binding in the caudate (rho=-0.42;P<0.05) and putamen (rho=-0.41;P<0.05), and with lower [11C]PE2I binding only in the putamen (rho=-0.69;P<0.001).
Conclusion: Our findings demonstrate loss of PDE10A expression very early in the course of Parkinson’s disease, which is comparable to DAT loss, and is associated with the gradual increase of motor symptom burden in different disease stages.
To cite this abstract in AMA style:
G. Pagano, H. Wilson, T. Yousaf, F. Niccolini, N. Khan, D. Martino, R. Gunn, E. Rabiner, P. Piccini, T. Foltynie, M. Politis. Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/comparison-of-pde10a-and-dat-expression-as-markers-of-disease-burden-in-early-parkinsons-disease/. Accessed May 10, 2025.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/comparison-of-pde10a-and-dat-expression-as-markers-of-disease-burden-in-early-parkinsons-disease/